Dysplasias (CIN, SIL) of the cervix uteri in womenPatanov, NIaneva, R
Dysplasia, Carcinoma in Situ, and Invasive Carcinoma of the Cervix Uteri in Previously Screened WomenThe authors have reviewed smears from previously screened women who developed dysplasia, carcinoma in situ, or invasive carcinoma.The study had two main purposes:to evaluate if the process had ...
In order to study when recurrences appear following conization for dysplasia or cancer in situ of the cervix uteri, a series of 477 patients has been investigated. They all underwent conization at Sabbatsberg 1965–1970. Among the 181 cases of dysplasia two developed recurrences one respectively th...
WOMEN WITH DYSPLASIA OR CARCINOMA OF THE CERVIX UTERIBuckley, DHarris, R W CDoll, RVessey, M PWilliams, P T
WileyInternational Journal of CancerForslund O, Miriam Elfstrom K, Lamin H, Dillner J. 2018. HPV-mRNA and HPV-DNA detection in samples taken up to seven years before severe dysplasia of cervix uteri. Int J Cancer https://doi.org/10.1002/ijc.31819....
Characteristics of women with dysplasia or carcinoma in situ of the cervix uteri. Brit J Cancer 1980; 42: 359-69.Harris RWC, Briton LA, Cowdell RH, et al. Characteristics of women with dysplasia or carcinoma in situ of the cervix uteri. Br J Cancer 1980;42:359-369....
Follow-up stud- ies in dysplasia and cancer in situ of the cervix uteri. Acta Obstet Gynaecol Stand 1978;57:69-71.Vaclavinkova V, Hedman AK, Nasiell K. Follow-up studies in dys- plasia and cancer in situ of the cervix uteri. Acta Obstet Gynecol Scand 1978;57:69-71....
Follow-up stud- ies in dysplasia and cancer in situ of the cervix uteri. Acta Obstet Gynaecol Stand 1978;57:69-71.Vaclavinkova V, Hedman AK, Nasiell K. Follow-up studies in dys- plasia and cancer in situ of the cervix uteri. Acta Obstet Gynecol Scand 1978;57:69-71....
HPV-mRNA and HPV-DNA detection in samples taken up to seven years before severe dysplasia of cervix uteriHPV-mRNAHPV-DNACINRandomized clinical trials using human papillomavirus (HPV) DNA testing have found increased protection against cervical cancer and HPV-based screening is globally recommended for...
A method for treating mild dysplasia of cervix uteri (CIN I) caused by papilloma virus comprises the oral use of biologically active additive based on indol-3-carbinol, one capsule twice a day for three months and immunomodulating therapy under periodical cytological control. For controlling the ...